Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 10/20 | 0.62 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.62 |
| ▸ | AKT2 | P31751 | 3/20 | 0.60 |
| ▸ | GSK3B | P49841 | 2/20 | 0.60 |
| ▸ | KIT | P10721 | 1/20 | 0.60 |
| ▸ | LCK | P06239 | 1/20 | 0.59 |
| ▸ | JAK2 | O60674 | 3/20 | 0.58 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | JAK1 | P23458 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1050141 | 0.94 | AKT2 (0.63) | JAK3DOT1LAKT2GSK3BKIT | |
| SCHEMBL31050016 | 0.94 | AKT2 (0.63) | JAK3DOT1LAKT2GSK3BKIT | |
| SCHEMBL31050017 | 0.85 | JAK3 (0.60) | JAK3DOT1LAKT2GSK3BKIT | |
| Trifluoroacetic Acid SCHEMBL30023792 | 0.83 | JAK3 (0.52) | JAK3DOT1LAKT2GSK3BKIT | |
| SCHEMBL1818852 | 0.77 | JAK3 (1.00) | JAK3DOT1LAKT2GSK3BKIT | |
| SCHEMBL31550436 | 0.77 | JAK3 (0.93) | JAK3DOT1LAKT2GSK3BKIT | |
| SCHEMBL3952874 | 0.77 | JAK3 (0.75) | JAK3DOT1LAKT2GSK3BKIT | |
| SCHEMBL1531444 | 0.77 | DOT1L (1.00) | JAK3DOT1LAKT2GSK3BKIT | |
| SCHEMBL1531600 | 0.77 | DOT1L (1.00) | JAK3DOT1LAKT2GSK3BKIT | |
| SCHEMBL1531446 | 0.77 | DOT1L (1.00) | JAK3DOT1LAKT2GSK3BKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118530260-A | Fused bicyclic derivatives, preparation method thereof and application thereof in medicines | 江苏恒瑞医药股份有限公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-118530261-A | Fused bicyclic derivatives, preparation method thereof and application thereof in medicines | 江苏恒瑞医药股份有限公司 | 2024-08-23 | — | — | CN | disclosed |
| US-20230148417-A1 | FUSED BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230148417-A1 | FUSED BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230148417-A1 | FUSED BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| EP-4122922-A1 | FUSED BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2023-01-25 | — | — | EP | disclosed |
| EP-4122922-A1 | FUSED BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2023-01-25 | — | — | EP | disclosed |
| CN-115397815-A | Condensed bicyclic derivative, preparation method and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2022-11-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148417-A1 | FUSED BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | WEE2, AKT1S1, WEE1 | JAK3 509/4885DOT1L 3023/4885AKT2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.